USCWA
VRTX icon

U.S. Capital Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

U.S. Capital Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,370
Closed -$1.15M – 934
2025
Q1 		$1.15M Buy
2,370
+93
+4% +$43.3K 0.04% 396
2024
Q4 		$917K Sell
2,277
-941
-29% -$436K 0.03% 440
2024
Q3 		$1.5M Buy
3,218
+986
+44% +$474K 0.05% 295
2024
Q2 		$1.05M Sell
2,232
-137
-6% -$59.5K 0.04% 340
2024
Q1 		$990K Buy
2,369
+845
+55% +$357K 0.04% 344
2023
Q4 		$620K Buy
1,524
+688
+82% +$254K 0.02% 411
2023
Q3 		$291K Sell
836
-13,184
-94% -$4.61M 0.01% 524
2023
Q2 		$4.93M Sell
14,020
-358
-2% -$121K 0.23% 101
2023
Q1 		$4.53M Sell
14,378
-252
-2% -$75.6K 0.21% 110
2022
Q4 		$4.22M Sell
14,630
-563
-4% -$172K 0.2% 113
2022
Q3 		$4.4M Sell
15,193
-545
-3% -$157K 0.22% 100
2022
Q2 		$4.43M Sell
15,738
-669
-4% -$179K 0.19% 109
2022
Q1 		$4.28M Sell
16,407
-703
-4% -$167K 0.16% 138
2021
Q4 		$3.76M Sell
17,110
-494
-3% -$96.1K 0.15% 155
2021
Q3 		$3.19M Buy
+17,604
New +$3.44M 0.14% 173

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

U.S. Capital Wealth Advisors's VRTX Position: Q2 2025 in Review

U.S. Capital Wealth Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 2,370 shares — an estimated $1.15M sold.

U.S. Capital Wealth Advisors first reported a position in VRTX in Q3 2021 and held it in 15 quarters. The position peaked at $4.93M in Q2 2023. 1,559 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

  • U.S. Capital Wealth Advisors reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • U.S. Capital Wealth Advisors sold 2,370 Vertex Pharmaceuticals shares in Q2 2025, an estimated $1.15M.
  • U.S. Capital Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q3 2021 and held it in 15 quarters.
  • U.S. Capital Wealth Advisors's Vertex Pharmaceuticals position peaked at $4.93M in Q2 2023.
  • 1,559 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on U.S. Capital Wealth Advisors's 13F filing for Q2 2025, filed 14 Jul 2025.